Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-135 in Chronic Kidney Disease
19 nov. 2018 07h00 HE
|
Breathtec Biomedical Inc.
Planning Phase II Trial VANCOUVER, B.C., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI)...